Scientists found the treat stops the formation of deadly oral tumours thanks to cancer-fighting chemicals found in the cocoa ...

VYNE Therapeutics Inc., a Delaware-based biopharmaceutical company, recently disclosed significant developments in its clinical trials concerning VYN202, a novel BD2-Selective BET Inhibitor. The ...

SHANGHAI, Dec. 23, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, ...

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers have investigated this with promising results. For the first time, it was possible to identify patient ...

Moderate-to-vigorous physical activity (MVPA) in young childhood is not associated with executive function in middle ...

Kaempferol's role in Treg development is linked to Aldh1a2 activation in dendritic cells, highlighting its potential in ...

Wang J, Yang J‐Y, Durairaj P, Wang W, Wei D‐Y, Tang S, et al. Discovery of β‐nitrostyrene derivatives as potential quorum sensing inhibitors for biofilm inhibition and antivirulence factor ...

The control group, which had unlimited access to food, saw normal hair regrowth. However, both intermittent fasting groups ...

Iron-chelating pyoverdines from environmental Pseudomonas spp. show promising antibacterial activity against key human pathogens through the induction of iron starvation, while associated toxicity for ...

L1-blocking antibody is now approved for metastatic or locally advanced cutaneous SCC in adults who are not candidates for curative surgery or curative radiation.

Prostate cancer remains a global health challenge, ranking as the second most commonly diagnosed cancer among men. Although ...